In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Vericel, with a price target of $60.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that highlight Vericel’s strong growth potential and strategic positioning. The company’s MACI product line is showing robust growth, with a 21% year-over-year increase in revenue for the second quarter of 2025, and the expansion of its surgeon customer base is a positive indicator of sustained demand. The early success of MACI Arthro, evidenced by the training of approximately 600 surgeons and the high number of biopsies performed, suggests a promising future for this new product line.
Furthermore, Vericel’s burn care franchise is also performing well, with Epicel and NexoBrid sales showing significant year-over-year growth. Despite conservative guidance for the second half of 2025, the underlying business fundamentals appear strong, and there is potential for further upside, particularly if Vericel’s partner, MediWound, secures a new BARDA contract. These factors, combined with the strategic decision to expand the sales force earlier than planned, underpin Ramakanth’s confidence in Vericel’s long-term growth trajectory.
In another report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $58.00 price target.